FIELD: pharmaceuticals.
SUBSTANCE: present invention provides for the compound of formula I, which is useful in the pharmaceutical industry
,
where R1, R2, R3 is selected from H or OR6; R6 is selected from OH, acetyl, tert-butylcarbonyl,
, 
, 
.
EFFECT: new compounds are proposed that are effective for the preparation of drugs for the treatment of coronary heart disease.
1 cl, 4 ex, 1 tbl, 5 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| FURIN INHIBITORS | 2019 |
|
RU2799824C2 |
| SYMMETRIC AND ASYMMETRIC DERIVATIVES OF DIPHENYLUREA (VARIANTS), PHARMACEUTICAL COMPOSITION, METHOD FOR INHIBITION OF RAF KINASE- MEDIATED TUMOR CELLS PROLIFERATION | 1998 |
|
RU2247109C9 |
| TRICYCLIC COMPOUNDS PROVIDING DESTRUCTION OF IKAROS PROTEIN AND AIOLOS PROTEIN | 2020 |
|
RU2833608C2 |
| METHOD FOR INHIBITION OF RAF KINASE-MEDIATED GROWTH OF TUMOR CELLS, HETEROCYCLIC UREA DERIVATIVES (VARIANTS), PHARMACEUTICAL COMPOSITION (VARIANTS) | 1998 |
|
RU2232015C2 |
| BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SAID DERIVATIVES, PRODUCTION AND USE THEREOF | 2005 |
|
RU2374234C2 |
| CETP INHIBITORS | 2006 |
|
RU2513107C2 |
| INHIBITORS, A METHOD OF THEIR PREPARATION AND USE | 2019 |
|
RU2806033C2 |
| SUBSTITUTED PYRAZOLOPYRIMIDINES AND SUBSTITUTED PURINES AND USE THEREOF AS INHIBITORS OF UBIQUITIN-SPECIFIC PROCESSING PROTEASE 1 (USP1) | 2019 |
|
RU2833222C2 |
| CYCLOPENTANE COMPOUNDS | 2019 |
|
RU2794997C2 |
| DERIVATIVES OF GALANTHAMINE, METHOD FOR THEIR PREPARING, MEDICINAL AGENT BASED ON THEREOF AND METHOD FOR ITS PREPARING | 2001 |
|
RU2241001C2 |
